SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending as investors monitor its recent inclusion in the Russell 2000 and 3000 indexes, which has sparked significant debate regarding potential liquidity inflows versus ongoing volatility and dilution concerns. The community is deeply divided, with bulls highlighting the company's expanding defense contracts and drone sector tailwinds, while bears remain focused on persistent downward price trends and recent resale registration filings.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is experiencing significant upward momentum and record volume as the community anticipates major catalysts, including the 80th trial event and potential buyout interest. The stock's rapid appreciation has sparked intense debate over a potential short squeeze, with investors closely watching borrowing fees and institutional activity while debating the long-term potential of the company's oncology pipeline.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is trending following a significant earnings beat and record backlog, which has fueled investor enthusiasm despite mixed forward guidance. The community is actively debating the stock's potential for a momentum-driven squeeze versus concerns regarding internal risk factors and ongoing cybersecurity scrutiny.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is rallying as traders closely track the firm's pivot toward solid-state transformer (SST) technology for the AI data center market. The community is actively debating the stock's potential for a massive short squeeze and long-term mean reversion, with many focused on institutional accumulation and insider buying as indicators of future growth.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy Enterprises is trending as investors react to the company's progress in scaling automated manufacturing at its second facility and securing significant purchase orders through its Frontier Power USA partnership. The community is actively debating the company's growth trajectory against the backdrop of increased energy demand from AI data centers, with many traders monitoring short interest and the potential for a technical breakout toward double-digit price levels.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire is gaining momentum following a new contract with Taiwan Color Optics to deliver its Penguin Mk2.5 uncrewed aerial system to the Taiwan Coast Guard. The community is actively discussing this shift toward defense and drone technology, with many investors closely tracking institutional liquidity trends and sector-wide rotation while anticipating further growth in the company's defense-related backlog.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is trending as investors react to a short report alleging discrepancies in order reporting and manufacturing, which the community is actively countering by pointing to the company's real-world customer traction and defense-sector partnerships. Traders are currently split between viewing the volatility as a liquidity trap meant to shake out retail investors and a necessary technical correction as the stock navigates broader institutional sell-side pressure.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is attracting investor attention due to robust revenue growth and a looming court decision regarding Medicare reimbursement, which has sparked intense debate over the stock's future value. Community sentiment remains polarized, with many shareholders closely tracking institutional accumulation and potential buyout interest while expressing frustration over the lack of near-term catalysts and management's communication strategy.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is experiencing intense volatility as investors react to Phase 3 trial data that showed best-in-class efficacy for obefazimod while simultaneously sparking concerns over potential malignancy signals in the higher-dose arm. Community discussion is heavily divided between retail investors viewing the sell-off as a manipulative overreaction to noise and institutional analysts who are downgrading the stock, citing increased regulatory risks and a more complex path to approval or acquisition.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail investors speculate on near-term catalysts, including potential international expansion for its Anktiva therapy and upcoming Q2 sales reporting. The community is actively debating the impact of the stock's recent performance on institutional holdings and short interest, while dismissing noise surrounding index rebalancing in favor of long-term growth driven by global manufacturing and clinical progress.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tamara A Favorito Expands Holdings With $51K Zevra Therapeutics Stock Options Acquisition

A notable acquisition unfolded on June 18, as Favorito, Director at Zevra Therapeutics (NASDAQ:ZVRA), reported the acquisition of stock options for 30,000 shares in an SEC filing.
What Happened: A Form 4 filing from theread more...

Corey M. Watton Seizes Opportunity: Acquires $51K Worth Of Zevra Therapeutics Stock Options

In a recent SEC filing, it was disclosed that Corey M. Watton, Board Member at Zevra Therapeutics (NASDAQ:ZVRA), made a noteworthy acquisition of company stock options on June 18,.
What Happened: A Form 4 filing fromread more...

A Noteworthy Decision By Thomas Anderson As Acquires $51K In Zevra Therapeutics Stock Options

In a new SEC filing on June 18, it was unveiled that Anderson, Director at Zevra Therapeutics (NASDAQ:ZVRA), acquired stock options for 30,000 shares.
What Happened: Uncovered in a Form 4 filing on Thursday with theread more...

Alicia Secor Takes A Bullish Stance, Acquiring $51K Worth Of Zevra Therapeutics Stock Options

A noteworthy insider acquisition was disclosed on June 18, as Secor, Board Member at Zevra Therapeutics (NASDAQ:ZVRA), reported the acquisition of stock options for 30,000 shares.
What Happened: Uncovered in a Form 4read more...

Douglas W Calder Makes Strategic Play: Invests $51K In Zevra Therapeutics Stock Options

In a new SEC filing on June 18, it was unveiled that Calder, Board Member at Zevra Therapeutics (NASDAQ:ZVRA), acquired stock options for 30,000 shares.
What Happened: Calder, Board Member at Zevra Therapeutics,read more...

Big News: Alvin Shih Adds $51K In Zevra Therapeutics Stock Options Io Portfolio

In a new SEC filing on June 18, it was unveiled that Shih, Board Member at Zevra Therapeutics (NASDAQ:ZVRA), acquired stock options for 30,000 shares.
What Happened: In a recent Form 4 filing with the U.S. Securitiesread more...

ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today?

Equity

Zevra Therapeutics shares saw a series of positive brokerage actions after the company asked the U.S. Food and Drug Administration to add a new patent for its Miplyffa drug to the Orange Book.

ZVRA Stock ‘Way Undervalued’? Analyst Sees 117% Upside After Patent Extends Exclusivity Till 2041 For Sole Approved Drug

Zevra said in a statement that it has asked the U.S. Food and Drug Administration to add its new patent for its drug MIPLYFFA to its official list.


Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates

Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of +184.36% and +15.51%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -29.46% and -15.29%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$14.01
Prev Close	$13.52
Open	$13.53
Dividend Yield	0.00%
50-Day Moving Average	$11.28
Beta	0.84
Avg. Volume	1.97M
PE Ratio	6.28

52-Week High	$14.27
52-Week Low	$7.16
Market Capitalization	$799.24M
EPS (Annual)	$1.35
Price to Book	3.88
Revenue Per Employee	$1.75M

Feed

News

Sentiment

Earnings

Fundamentals

Info

ZVRAZevra Therapeutics Inc

Latest ZVRA News